eShowcase: CTSD Version 2.5
CTSD Version 2.5 provides improved data visualization and enhanced user interface
CTSD Version 2.5 provides improved data visualization and enhanced user interface
Phase Forward (Waltham, MA) has released Version 2.5 of its Clinical Trials Signal Detection (CTSD) system. CTSD detects, evaluates, and tracks potential safety signals, which allows biopharmaceutical companies to analyze and classify potential safety signals, develop a product safety profile, and make more informed decisions earlier in the drug development process.
CTSD 2.5 adds an enhanced user interface that features summary displays, data visualization tools, and access to trial data without programming. The user interface's interactive displays facilitate safety review workflow by including patient level drill downs, Lab Trend graphs, an Exposure Summary graph, and Kaplan-Meier plots. It also offers Hy's Law alerts and a full set of Standardized MedDRA Queries (SMQs).
The product is integrated with Phase Forward's Web Submission Data Manager (WebSDM) platform and offers CDISC support.
Phase Forward, (781) 890-7878, www.phaseforward.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
